Cabrera Antonio G, Prodhan Parthak, Cleves Mario A, Fiser Richard T, Schmitz Michael, Fontenot Eudice, McKamie Wesley, Chipman Carl, Jaquiss Robert D B, Imamura Michiaki
Department of Pediatrics, The Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
Congenit Heart Dis. 2011 May-Jun;6(3):202-8. doi: 10.1111/j.1747-0803.2011.00506.x. Epub 2011 Mar 31.
Many centers are able to emergently deploy extracorporeal membrane oxygenation (ECMO) as support in children with refractory hemodynamic instability, but may be limited in their ability to provide prolonged circulatory support or cardiac transplantation. Such patients may require interhospital transport while on ECMO (cardiac mobile [CM]-ECMO) for additional hemodynamic support or therapy. There are only three centers in the United States that routinely perform CM-ECMO. Our center has a 20-year experience in carrying out such transports. The purpose of this study was twofold: (1) to review our experience with pediatric cardiac patients undergoing CM-ECMO and (2) identify risk factors for a composite outcome (defined as either cardiac transplantation or death) among children undergoing CM-ECMO.
Retrospective case series.
Cardiovascular intensive care and pediatric transport system.
Children (n = 37) from 0-18 years undergoing CM-ECMO transports (n = 38) between January 1990 and September 2005.
None.
A total of 38 CM-ECMO transports were performed for congenital heart disease (n = 22), cardiomyopathy (n = 11), and sepsis with myocardial dysfunction (n = 4). There were 18 survivors to hospital discharge. Twenty-two patients were transported a distance of more than 300 miles from our institution. Ten patients were previously cannulated and on ECMO prior to transport. Thirty-five patients were transported by air and two by ground. Six patients underwent cardiac transplantation, all of whom survived to discharge. After adjusting for other covariates post-CM-ECMO renal support was the only variable associated with the composite outcome of death/need for cardiac transplant (odds ratio = 13.2; 95% confidence interval, 1.60--108.90; P = 0.003). There were two minor complications (equipment failure/dysfunction) and no major complications or deaths during transport.
Air and ground CM-ECMO transport of pediatric patients with refractory myocardial dysfunction is safe and effective. In our study cohort, the need for post-CM-ECMO renal support was associated with the composite outcome of death/need for cardiac transplant.
许多中心能够紧急部署体外膜肺氧合(ECMO)来支持难治性血流动力学不稳定的儿童,但在提供长期循环支持或心脏移植方面可能能力有限。此类患者在接受ECMO治疗期间(心脏移动[CM]-ECMO)可能需要转院以获得额外的血流动力学支持或治疗。美国仅有三个中心常规开展CM-ECMO。我们中心在进行此类转运方面有20年经验。本研究目的有两个:(1)回顾我们对接受CM-ECMO的小儿心脏患者的经验;(2)确定接受CM-ECMO的儿童中复合结局(定义为心脏移植或死亡)的危险因素。
回顾性病例系列。
心血管重症监护和儿科转运系统。
1990年1月至2005年9月期间0至18岁接受CM-ECMO转运(n = 38)的儿童(n = 37)。
无。
共进行了38次CM-ECMO转运,病因包括先天性心脏病(n = 22)、心肌病(n = 11)和伴有心肌功能障碍的脓毒症(n = 4)。18名患者存活至出院。22名患者从我们机构被转运至300多英里外的地方。10名患者在转运前已插管并接受ECMO治疗。35名患者通过空运转运,2名通过陆运转运。6名患者接受了心脏移植,均存活至出院。在调整其他协变量后,CM-ECMO后肾脏支持是与死亡/心脏移植需求这一复合结局相关联的唯一变量(比值比 = 13.2;95%置信区间,1.60 - 108.90;P = 0.003)。转运期间有2例轻微并发症(设备故障/功能障碍),无重大并发症或死亡。
对难治性心肌功能障碍的小儿患者进行空运和陆运CM-ECMO是安全有效的。在我们的研究队列中,CM-ECMO后肾脏支持需求与死亡/心脏移植需求这一复合结局相关。